Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $59.20

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have earned an average recommendation of “Buy” from the eight ratings firms that are covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $59.20.

Several equities research analysts have issued reports on ARCT shares. Wells Fargo & Company decreased their price objective on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. BTIG Research set a $48.00 price objective on shares of Arcturus Therapeutics and gave the company a “buy” rating in a research note on Monday, March 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. HC Wainwright dropped their target price on Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Finally, Canaccord Genuity Group reduced their price target on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a report on Monday, March 10th.

Arcturus Therapeutics Stock Down 2.0 %

ARCT stock opened at $8.91 on Friday. Arcturus Therapeutics has a 52 week low of $8.04 and a 52 week high of $45.00. The company has a market cap of $241.64 million, a price-to-earnings ratio of -4.01 and a beta of 3.41. The business has a fifty day simple moving average of $14.44 and a 200-day simple moving average of $17.19.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The firm had revenue of $22.77 million during the quarter, compared to analysts’ expectations of $44.64 million. As a group, analysts expect that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ARCT. Wellington Management Group LLP lifted its holdings in Arcturus Therapeutics by 0.8% during the 4th quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company’s stock worth $1,647,000 after buying an additional 742 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Arcturus Therapeutics by 10.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after acquiring an additional 846 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in Arcturus Therapeutics by 5.0% during the fourth quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company’s stock worth $316,000 after purchasing an additional 883 shares during the last quarter. Virtus ETF Advisers LLC boosted its holdings in Arcturus Therapeutics by 38.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 1,132 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in Arcturus Therapeutics by 7.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company’s stock valued at $323,000 after purchasing an additional 1,279 shares during the last quarter. 94.54% of the stock is owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.